• Carl Zeiss Meditec revenue fell 2.9% to €1.55 billion in the first nine months of 2025/26.
• EBITA dropped to €108.4 million, cutting the EBITA margin by 4 percentage points to 7%.
• Adjusted EBITA declined to €124.5 million, pushing the adjusted margin down 3.1 percentage points to 8%.
• Ophthalmology revenue slid 4.8% to €1.19 billion, while Microsurgery climbed 3.8% to €362.3 million.
• FY 2025/26 revenue is forecast at about €2.15 billion-€2.2 billion, with an adjusted EBITA margin of 8%-10%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Carl Zeiss Meditec AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2378280_en) on August 06, 2026, and is solely responsible for the information contained therein.